How Supplement Law Works: The DSHEA Premarket Gap

Dietary supplements reach store shelves without FDA premarket approval because federal law places them in a different legal category than medicines. Under the Dietary Supplement Health and Education Act of 1994, known as DSHEA, supplements are regulated as a class of food, and the manufacturer, not the FDA, is responsible for confirming that a product is safe and its labeling truthful before it goes on sale. The agency generally steps in only after a product is already on the market. The familiar line "This statement has not been evaluated by the Food and Drug Administration" is not fine print to skim past; it is a precise legal signal about how little review the claim above it received.

Two systems, one gap

For a prescription drug, a sponsor must show the FDA substantial evidence of both safety and effectiveness before the product can be sold. Having worked on the drug-development and regulatory side of that framework, I can say its defining feature is that the burden sits with the sponsor and the review happens first. Supplements invert this. As the FDA states on its dietary supplements pages, the agency does not approve supplements or their labeling before they are marketed. The manufacturer must ensure the product is neither adulterated nor misbranded, but the FDA carries the burden of proving a marketed product unsafe, or its labeling false, before it can force changes. That reversal is the premarket gap: the review a drug undergoes before launch simply does not exist for a supplement.

What "food, not drug" changes

This category choice cascades. A drug maker files data and waits for a decision; a supplement maker can formulate, label, and ship, then notify the agency afterward for certain claims. New dietary ingredients, meaning those not sold in the United States before October 1994, trigger a safety notification, and all manufacturers must follow current good manufacturing practice rules and report serious adverse events. None of that is premarket approval. It is a post-market safety net, with the agency reacting to problems rather than screening products in advance.

What a label can and cannot claim

DSHEA allows three main categories of claim on a supplement label: nutrient content claims, health claims, and structure/function claims. Structure/function claims are the ones most people picture, and they are the least reviewed. According to the FDA's structure/function claims guidance, these statements may describe the role of a nutrient or ingredient in maintaining normal structure or function, as in "supports immune function" or "helps maintain healthy cholesterol levels already within the normal range." What they may not do is cross into disease territory.

The disease line

The moment a label says a product diagnoses, treats, cures, prevents, or mitigates a disease, the law treats that product as a drug, and an unapproved one at that. "Supports joint comfort" is a structure/function claim. "Treats arthritis" is a disease claim, and it is illegal without drug approval. This single line explains most supplement marketing language. The vague, physiology-flavored phrasing you see is not accidental; it is the widest lane a company can drive in without triggering the drug rules.

Notification is not approval

For structure/function claims, the manufacturer must submit a notification to the FDA no later than 30 days after first marketing the product with the claim, a requirement codified at 21 CFR 101.93 and grounded in section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act. Two things about that notification matter. It happens after the product is already for sale, and it is not a review of whether the claim is true. The company is required to hold substantiation that the claim is truthful and not misleading, but it files the text of the claim, not the evidence behind it. The FDA logging a claim is record-keeping, not endorsement.

What the disclaimer actually signals

That is why the mandatory disclaimer exists, and why its wording is exact. 21 CFR 101.93 requires structure/function claims to carry, in boldface, "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." Read literally, it is true. No agency vetted the specific claim, and the product is not an approved treatment for anything. The disclaimer is neither a warning that the product is dangerous nor a hint that it works. It marks the boundary of what was reviewed, which for the claim itself is nothing.

The placement of that disclaimer is now under active reconsideration. In a December 2025 letter to the dietary supplement industry, the FDA said it had received requests to amend the placement rule at 21 CFR 101.93(d) and, absent significant concerns, is likely to propose a rule change. In the meantime the agency said it intends to exercise enforcement discretion for the requirement that the disclaimer appear on every panel where such a claim appears. Two points keep this in perspective. It is a proposal and an enforcement-discretion posture, not a final rule, and it addresses where the disclaimer sits on the package, not whether the underlying claim was ever evaluated. The substance of the signal is unchanged.

Reading a label as an evidence question

Understanding the gap turns a label into a set of questions rather than a verdict. Is the phrasing a structure/function claim or a disease claim? Is there independent evidence for the ingredient at the dose used, or only a physiology-shaped sentence and a disclaimer? Does "clinically studied" describe the finished product, or a single ingredient in an unrelated study? The law does not certify that a supplement works; it certifies that the maker stayed inside the claim rules. Those are very different guarantees, and the disclaimer is the law's own reminder of the difference. This article is educational and not medical advice; decisions about supplements belong in a conversation with your own qualified clinician.